Report LibraryAll Reports
Datamonitor Healthcare Oncology Disease Analysis: Chronic Myeloid Leukemia (CML)
December 24, 2021
Since the approval of Gleevec in 2001, tyrosine kinase inhibitors (TKIs) have been a mainstay in the treatment of chronic myeloid leukemia (CML). TKIs have greatly improved survival, with a five-year relative survival rate of 70.6% and most chronic-phase patients having a normal life expectancy. However, although TKIs have reduced the rate of progression to advanced phases, survival among advanced phase patients remains poor.
The success of Gleevec gave rise to a new generation of TKIs which are influential across all lines of the treatment paradigm. Second-generation TKIs Sprycel and Tasigna dominate the second-line setting, and after demonstrating superiority over Gleevec in the first-line setting they also hold a large market share of the treatment-naïve patient population. Furthermore, second-generation TKI Bosulif, which was a later entry to the market, is influential in the third-line treatment setting. However, patent expiries for both Sprycel and Tasigna in the near future will hinder growth of the CML market in both the first- and second-line treatment settings.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Chronic Myelogenous Leukemia (CML)|